LA JOLLA, Calif., Aug. 8, 2017 /PRNewswire/ -- Regulus
Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company
leading the discovery and development of innovative medicines
targeting microRNAs, today announced that Jay Hagan, President and Chief Executive Officer
of Regulus, will present a company overview at the 2017 Wedbush
PacGrow Healthcare Conference in New York
City on Tuesday, August 15,
2017.
About Regulus
Regulus Therapeutics Inc. (Nasdaq: RGLS)
is a clinical stage biopharmaceutical company leading the discovery
and development of innovative medicines targeting microRNAs.
Regulus has leveraged its oligonucleotide drug discovery and
development expertise to develop a well-balanced microRNA
therapeutics pipeline complemented by a rich intellectual property
estate to retain its leadership in the microRNA field.
Regulus is advancing several programs in renal, hepatic and central
nervous systems diseases. Regulus maintains its corporate
headquarters in La Jolla,
CA. For more information, please visit
http://www.regulusrx.com.
Forward-Looking Statements
Statements contained in
this press release regarding matters that are not historical facts
are "forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995, including statements
associated with the expected ability of Regulus to undertake
certain activities and accomplish certain goals (including with
respect to development and other activities related to RG-012 or
RGLS4326), the projected timeline of clinical development
activities, and expectations regarding future therapeutic and
commercial potential of Regulus' business plans, technologies and
intellectual property related to microRNA therapeutics and
biomarkers being discovered and developed by Regulus. Because
such statements are subject to risks and uncertainties, actual
results may differ materially from those expressed or implied by
such forward-looking statements. Words such as "believes,"
"anticipates," "plans," "expects," "intends," "will," "goal,"
"potential" and similar expressions are intended to identify
forward-looking statements. These forward-looking statements are
based upon Regulus' current expectations and involve assumptions
that may never materialize or may prove to be incorrect.
Actual results and the timing of events could differ materially
from those anticipated in such forward-looking statements as a
result of various risks and uncertainties, which include, without
limitation, risks associated with the process of discovering,
developing and commercializing drugs that are safe and effective
for use as human therapeutics, and in the endeavor of building a
business around such drugs. These and other risks concerning
Regulus' financial position and programs are described in
additional detail in Regulus filings with the Securities and
Exchange Commission. All forward-looking statements contained
in this press release speak only as of the date on which they were
made. Regulus undertakes no obligation to update such statements to
reflect events that occur or circumstances that exist after the
date on which they were made.
View original content with
multimedia:http://www.prnewswire.com/news-releases/regulus-to-present-at-the-2017-wedbush-pacgrow-healthcare-conference-300501504.html
SOURCE Regulus Therapeutics Inc.